2. Search Result
Search Result
Results for "

misfolding

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125287
    (Rac)-Minzasolmin

    (Rac)-UCB0599; NPT200-11

    		 α-synuclein Neurological Disease
    (Rac)-Minzasolmin ((Rac)-UCB0599) is a brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. (Rac)-Minzasolmin can be used for research of Parkinson's disease .
    (Rac)-Minzasolmin
  • HY-18956
    (E/Z)-Icerguastat

    (E/Z)-Sephin1; (E/Z)-IFB-088

    		 Phosphatase Inflammation/Immunology
    (E/Z)-Icerguastat ((E/Z)-Sephin1) is a selective inhibitor of the phosphatase regulatory subunit PPP1R15A (R15A). (E/Z)-Icerguastat can be used for protein misfolding diseases research .
    (E/Z)-Icerguastat
  • HY-B1153
    Glafenine
    1 Publications Verification

    Glafenin

    		 Anion Exchangers Inflammation/Immunology
    Glafenine is a non-steroidal anti-inflammatory drug (NSAID) that can be used for pain relief research. Glafenine can also antagonize the misfolding of SLC4A11 protein .
    Glafenine
  • HY-B1153A
    Glafenine hydrochloride
    1 Publications Verification

    Glafenin hydrochloride

    		 Anion Exchangers Inflammation/Immunology
    Glafenine hydrochloride is a non-narcotic analgesic and non-steroidal anti-inflammatory drug. It is an ABCG2 inhibitor with an IC50 of 3.2 μM. Glafenine can also antagonize the misfolding of SLC4A11 protein .
    Glafenine hydrochloride
  • HY-111447
    VAS 3947

    		NADPH Oxidase Apoptosis Cardiovascular Disease Cancer
    VAS 3947, a specific NADPH oxidase (NOX) inhibitor, exerts a potent antiplatelet effect. VAS3947 induces apoptosis independently of anti-NOX activity, via UPR activation, mainly due to aggregation and misfolding of proteins .
    VAS 3947
  • HY-18956B
    (E/Z)-Icerguastat acetate

    (E/Z)-Sephin1 acetate; (E/Z)-IFB-088 acetate

    		 Phosphatase Inflammation/Immunology
    (E/Z)-Icerguastat ((E/Z)-Sephin1) acetate is a selective inhibitor of the phosphatase regulatory subunit PPP1R15A (R15A). (E/Z)-Icerguastat acetate can be used for protein misfolding diseases research .
    (E/Z)-Icerguastat acetate
  • HY-161895
    CFTR corrector 14

    		CFTR Others
    CFTR corrector 14 (Compound SVQ26) is a class 3 corrector for cystic fibrosis transmembrane conductance regulator (CFTR), that promotes the CFTR activity (EC50 of 3.08 μM with presence of C1 class corrector VX-809). CFTR corrector 14 regulates the mutant-caused misfolding and impaired function of the CFTR protein. CFTR corrector 14 can be used in research about cystic fibrosis .
    CFTR corrector 14
  • HY-P10494
    FEFEFKFK

    		Amyloid-β Neurological Disease
    FEFEFKFK is an octapeptide that self-assembles into fibrillar structures. FEFEFKFK is able to form gels at concentrations greater than about 7 mg/mL. The self-assembly and gelation properties of FEFEFKFK help to understand the mechanism of amyloid fibril formation in protein misfolding diseases such as Alzheimer's disease and Parkinson's disease .
    FEFEFKFK
  • HY-18956A
    (E/Z)-Icerguastat hydrochloride

    (E/Z)-Sephin1 hydrochloride; (E/Z)-IFB-088 hydrochloride

    		 Phosphatase Neurological Disease
    (E/Z)-Icerguastat hydrochloride ((E/Z)-Sephin1 hydrochloride) is a selective inhibitor with activity that prolongs the phosphorylation effects of eIF2α. (E/Z)-Icerguastat hydrochloride protects cells from defects in proteostasis. (E/Z)-Icerguastat hydrochloride was shown to significantly extend the survival of infected prion mice in a mouse model. (E/Z)-Icerguastat hydrochloride effectively reduces PrPSc expression and prion sequence activity in various neuronal cell lines persistently infected with different prion strains .
    (E/Z)-Icerguastat hydrochloride
  • HY-160426
    Gcase activator 3

    		Glycosidase Neurological Disease
    Gcase activator 3 (compound 9Q) is a glucosidase (Glucosidase, GCase) activator that can partially stabilize GCase and increase its activity. Gcase activator 3 reduces mutant GCase protein misfolding and degradation in fibroblasts and dopaminergic midbrain neurons. Gcase activator 3 can be used in the study of Parkinson's disease (PD) and related synucleinopathies .
    Gcase activator 3
  • HY-121845
    4-Br-Bnlm

    		HSP Metabolic Disease
    4-Br-Bnlm is a selective inhibitor of glucose-regulated protein 94 (Grp94) with an EC50 value of 0.96 µM. 4-Br-Bnlm reduces the levels of mutant myocilin proteins as well as wild-type myocilin misfold in cells. 4-Br-Bnlm promotes the clearance of toxic formsof myocilin and reduces myocilin toxicity .
    4-Br-Bnlm
  • HY-138643
    Cl-NQTrp

    		Amyloid-β Neurological Disease
    Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein .
    Cl-NQTrp
  • HY-111022
    Icerguastat

    Sephin1; IFB-088

    		 Phosphatase Infection Inflammation/Immunology
    Icerguastat (Sephin1), a derivative of Guanabenz lacking the α2-adrenergic activity, is a selective inhibitor of the phosphatase regulatory subunit PPP1R15A (R15A). Icerguastat inhibits eIF2α dephosphorylation, thereby prolonging the protective response. Anti-prion effect .
    Icerguastat
  • HY-110365
    Icerguastat Carbonate

    Sephin1 Carbonate; IFB-088 Carbonate

    		 Phosphatase Infection
    Icerguastat (Sephin1) Carbonate, a derivative of Guanabenz lacking the α2-adrenergic activity, is a selective inhibitor of the phosphatase regulatory subunit PPP1R15A (R15A). Icerguastat Carbonate inhibits eIF2α dephosphorylation, thereby prolonging the protective response. Anti-prion effect .
    Icerguastat Carbonate
  • HY-123960A
    Raphin1 acetate
    3 Publications Verification

    		 Phosphatase Neurological Disease
    Raphin1 acetate is an orally bioavailable, selective inhibitor of the regulatory phosphatase PPP1R15B (R15B). Raphin1 acetate binds strongly to the R15B-PP1c holophosphatase (Kd=33 nM), and shows ~30-fold selective in binding R15B-PP1c over R15A-PP1c. Raphin1 acetate crosses the blood-brain barrier, and reduces organismal and molecular deficits in a mouse model of a protein misfolding disease .
    Raphin1 acetate
  • HY-123960
    Raphin1
    3 Publications Verification

    		 Phosphatase Neurological Disease
    Raphin1 is an orally bioavailable, selective inhibitor of the regulatory phosphatase PPP1R15B (R15B). Raphin1 binds strongly to the R15B-PP1c holophosphatase (Kd=33 nM), and shows ~30-fold selective in binding R15B-PP1c over R15A-PP1c. Raphin1 crosses the blood-brain barrier, and reduces organismal and molecular deficits in a mouse model of a protein misfolding disease .
    Raphin1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: